{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T21:09:51Z","timestamp":1779224991397,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T00:00:00Z","timestamp":1523404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.bcmd.2018.04.001","type":"journal-article","created":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T12:43:57Z","timestamp":1523277837000},"page":"71-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1"],"prefix":"10.1016","volume":"71","author":[{"given":"Pramod K.","family":"Mistry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Balwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagit N.","family":"Baris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadhami Ben","family":"Turkia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Andrew","family":"Burrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Charrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald F.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumita","family":"Danda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Dragosky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Drelichman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"El-Beshlawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Fraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selena","family":"Freisens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiaan","family":"Gaemers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgueniy","family":"Hadjiev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Lukina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Maison-Blanche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Pastores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Petakov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Judith","family":"Peterschmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Rosenbloom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa H.","family":"Underhill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2018.04.001_bb0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bcmd.2017.09.003","article-title":"Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy","volume":"68","author":"Zimran","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0010","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.2013.2","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants","volume":"93","author":"Hicks","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcmd.2017.01.006","article-title":"A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: evaluation of frequency, timing, and duration","volume":"68","author":"Peterschmitt","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bcmd.2017.11.001","article-title":"Therapeutic position of eliglustat","volume":"69","author":"Cox","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0025","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.bcmd.2018.04.001_bb0030","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2018.04.001_bb0035","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0045","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2018.04.001_bb0050","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","article-title":"Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2018.04.001_bb0055","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2018.04.001_bb0060","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0065","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.24877","article-title":"Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: the phase 3 ENGAGE trial","volume":"92","author":"Mistry","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0070","first-page":"17","article-title":"Clinical response to eliglustat in treatment-naive patients with Gaucher disease type 1: post-hoc comparison to imiglucerase-treated patients enrolled in the international collaborative Gaucher group Gaucher registry","volume":"8","author":"Ibrahim","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0075","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2008.12.015","article-title":"A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4\u202fweeks versus every 2\u202fweeks in the maintenance therapy of adult patients with Gaucher disease type 1","volume":"96","author":"Kishnani","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0080","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ajh.23383","article-title":"Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase","volume":"88","author":"Zimran","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0085","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bcmd.2014.05.004","volume":"53","author":"Pastores","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0090","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","article-title":"Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement","volume":"110","author":"Elstein","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2018.04.001_bb0095","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bcmd.2010.05.001","article-title":"Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply","volume":"46","author":"Zimran","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13023-015-0275-0","article-title":"Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1","volume":"10","author":"Stirnemann","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0110","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.7196\/SAMJ.2016.v106i6.11002","article-title":"Interruption of enzyme replacement therapy in Gaucher disease","volume":"106","author":"Goldblatt","year":"2016","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0115","first-page":"117","article-title":"Did the temporary shortage in supply of imiglucerase have clinical consequences? Retrospective observational study on 34 italian Gaucher type I patients","volume":"7","author":"Deroma","year":"2013","journal-title":"JIMD Rep."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bcmd.2010.05.002","article-title":"Enzyme replacement therapy \"drug holiday\": results from an unexpected shortage of an orphan drug supply in Australia","volume":"46","author":"Goldblatt","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcmd.2009.09.006","article-title":"Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease","volume":"44","author":"Hollak","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00005-014-0308-8","article-title":"Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3","volume":"63","author":"Machaczka","year":"2015","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0135","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","article-title":"Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy","volume":"129","author":"Cox","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2018.04.001_bb0140","first-page":"S119","article-title":"Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1 (abstract)","volume":"123","author":"Peterschmitt","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0145","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.ymgme.2016.11.155","article-title":"Two-year postmarketing safety experience with oral eliglustat in adults with type 1 Gaucher disease (abstract)","volume":"120","author":"Hou","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0150","series-title":"Summary of product characteristics","author":"CERDELGA\u2122","year":"2014"},{"key":"10.1016\/j.bcmd.2018.04.001_bb0155","series-title":"(eliglustat) ([package insert])","author":"CERDELGA\u2122","year":"2014"},{"key":"10.1016\/j.bcmd.2018.04.001_bb0165","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ajh.21305","article-title":"Life expectancy in Gaucher disease type 1","volume":"83","author":"Weinreb","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0170","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bcmd.2016.10.002","article-title":"Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy","volume":"68","author":"Weinreb","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0175","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","article-title":"Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease","volume":"71","author":"Weinreb","year":"2007","journal-title":"Clin. Genet."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0180","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","article-title":"Quality of life related to type 1 Gaucher disease: Spanish experience","volume":"14","author":"Giraldo","year":"2005","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0185","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1023\/A:1008859420641","article-title":"Quality of life assessment in adults with type 1 Gaucher disease","volume":"8","author":"Masek","year":"1999","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0190","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1008814105603","article-title":"The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study","volume":"7","author":"Damiano","year":"1998","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0195","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s10545-008-0868-z","article-title":"Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher registry","volume":"31","author":"Fairley","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ymgme.2006.08.009","article-title":"Phenotypic and genotypic heterogeneity in Gaucher disease type 1: a comparison between Brazil and the rest of the world","volume":"90","author":"Sobreira","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0205","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ymgme.2009.05.001","article-title":"Clinical and genetic study of Japanese patients with type 3 Gaucher disease","volume":"97","author":"Tajima","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2018.04.001_bb0210","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bcmd.2016.10.026","article-title":"Clinical and molecular characteristics of patients with Gaucher disease in Southern China","volume":"68","author":"Feng","year":"2018","journal-title":"Blood Cells Mol. Dis."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979618300792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979618300792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:33:00Z","timestamp":1761049980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979618300792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":41,"alternative-id":["S1079979618300792"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2018.04.001","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2018.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}